Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
Open Access
- 4 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 11 (1), 335
- https://doi.org/10.1186/1471-2407-11-335
Abstract
Background: Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer. This study was planned in order to contrast potential differences between female and male breast cancer in both tumor biological behavior and clinical management.Methods: MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone receptors, HER2 status).Results: 108 male/female matched-pairs were available for survival analyses. In our study men and women with breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range 54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI, 62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with poor patients outcome in MBC.Conclusion: Our comparative study revealed no survival differences between male and female breast cancer patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female breast cancer.Keywords
This publication has 31 references indexed in Scilit:
- Multidisciplinary Meeting on Male Breast Cancer: Summary and Research RecommendationsJournal of Clinical Oncology, 2010
- Male Breast Cancer: A Population-Based Comparison With Female Breast CancerJournal of Clinical Oncology, 2010
- MicroRNA expression profiling of male breast cancerBreast Cancer Research, 2009
- Immunohistochemical characterization of subtypes of male breast carcinomaBreast Cancer Research, 2009
- Men With Breast Cancer Have Same Disease-Specific and Event-Free Survival as WomenAnnals of Surgical Oncology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Male breast cancerThe Lancet, 2006
- Male Breast Cancer: Is the Incidence Increasing?Annals of Surgical Oncology, 2004
- Is Male Breast Cancer Similar or Different than Female Breast Cancer?Breast Cancer Research and Treatment, 2004
- An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patientsSurgery, 1999